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Abstract 
Marfan syndrome is an autosomal dominant heritable connective tissue disorder 
which involves primarily the skeletal, ocular and cardiovascular system. The 
incidence of MS is on average 1: 10000 with 25-30% of cases caused by sporadic 
mutations. 
The leading cause of premature death in these patients is progressive dilatation and 
subsequent dissection of the ascending thoracic aorta resulting in cardiac 
tamponade, and left ventricular failure due to aortic regurgitation. Life expectancy is 
primarily determined by the severity of cardiovascular involvement, and has improved 
substantially over the last 20 years due to the advances in surgical and medical 
management. 
The optimum management of Marfan patients includes a lifelong surveillance with 
particular emphasis placed on aortic behaviour. Preventive replacement of various 
portions of the aorta has been a major contribution for improved life expectancy in 
these patients. The different surgical and interventional treatment options currently 
available will be further outlined in this review. 
MeSH: Marfan syndrome, Surgical techniques, Thoracic Surgery, Long term 
outcome, Cardiovascular complications 
 
Introduction 
In 1896 Antoine Marfan, a professor of paediatrics, presented for the first time a 5 
year old girl with the phenotype of a connective tissue disorder. In 1931 the mode of 
inheritance with an autosomal dominant trait was discovered. 
During the 20th century, additional components of this syndrome became apparent, 
particularly the cardiovascular involvement with dilatation of the aortic root and the 
high risk of subsequent aortic dissection which was first reported in 1943.1 Diagnosis 
mainly relied on clinical criteria, until recently when the underlying gene defect on 
chromosome 15q21 was discovered in 1990.2 
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Cardiothoracic surgery, has become an accepted and proven treatment for elective 
as well as emergency surgery for aortic aneurysm and dissection, and thereby can 
be considered as the major contributing factor for the increased life expectancy in 
patients with Marfan syndrome (MFS). 
 
Pathophysiolgy and genetics 
By immunhistochemical studies of Marfan patients it was shown, that most of the 
patients with MFS display an abnormal pattern of microfibrils in the extracellular 
matrix. Further studies revealed a 350 kD protein named Fibrillin which was 
characterised to be the main component of the extracellular microfibrils, to be 
responsible for these abnormalities.3 Subsequently the fibrillin gene could be mapped 
to the long arm of chromosome 15 and in situ hybridisation assigned the gene locus 
to 15q15-21.2 However, genetic testing proved to be less reliable than expected, with 
only 66% mutation detection rate of patients diagnosed with MFS by the Ghent 
nosology. The reason for these fair results are based on the fact that there are a 
variable number of mutations, which precludes broad spectrum genetic screening. 
Furthermore Fibrillin mutations have also been detected in Marfan related disorders.3 
 
Diagnosis 
In 1986 the Berlin nosology of heritable connective tissue disorder was published 
which classified certain organ manifestations into groups with major and minor 
criteria.4 Further refinements were included in the Gent criteria and recently revised 
by De Paepe et al in 1996.5 The criteria are subdivided into the following organ 
systems: skeletal, ocular, cardiovascular, pulmonary, skin, dura and family 
respectively genetic history. For a clinical diagnosis of MS, in the absence of a 
positive family history, a person suspected to have MS should at least display major 
criteria in two organ systems and involvement of a third organ system. When patients 
have a positive family history, major criteria in one and minor criteria in another organ 
system is required.5 
Particular emphasis should be placed on the predominance of skeletal features in 
childhood, as this can lead to earlier diagnosis and more appropriate surveillance, of 
cardiovascular status. In younger patients with a family history of MFS who do no 
fulfil the diagnostic criteria as well as young patients who fail to meet criteria in one 
organ system are required to repeat evaluations on a regular basis until the age of 
18. 
Cardiovascular complications usually do not occur before the age of 16 years. A this 
point the aortic root dimensions approached the adult size so that one can refer to 
the recommendations for the adult population regarding aortic root dimensions which 
should be always measured in relation to body surface area.6 
Infrequently, the infantile form of Marfan syndrome occurs, which is characterised by 
mitral valve regurgitation and aortic root dilatation which become apparent during the 
first three months of life. Mortality is substantial with 14% of affected children dying 
during the first year of life.7 
 
Conservative and surgical considerations 
Cardiovascular manifestations in MFS include mitral valve prolapse and 
regurgitation, left ventricular dilatation, pulmonary artery dilatation, and aortic valve 
regurgitation secondary to aortic root dilatation which can be regarded the most 
common cause of morbidity through the increased risk of dissection and rupture 
when the aortic root diameter exceeds 5.5 cm. Obviously the outcome of prophylactic 
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aortic root surgery is superior over emergency surgery in the case of aortic 
dissection. 
Dissection involving the ascending aorta is an absolute indication for operation with 
the intention to replace the sinus of Valsalva and the ascending aorta and eventually, 
if affected, the aortic arch (figures 1-3). Treatment options regarding the aortic valve 
are outlined below. 
 
Figure 1 Three dimensional CT reconstruction of an acute aortic dissection type A 
extending until the ilac arteries. The primary entry tear in the ascending aorta is seen 
(A). The re-entry just distal the left subclavian artery is also seen (B). 
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Figure 2 Intraoperative view of an acute type A dissection. One can clearly see the 
site of the entry tear in the intima 1.5 cm above the aortic valve (A). 
 
 
Figure 3 CT Scan showing a huge ascending aortic aneurysm with a maximum 
diameter of 8.2 cm. 
 
 
The exact timing of operation is crucial in a Marfan patient. The following parameters 
should be taken into consideration when planning surgery: 
 Diameter of the ascending thoracic aorta: aneurysms larger than 6 cm 
have a 10% increased risk of rupture. Elective replacement indication for 
Marfan patients is suggested when the thoracic aorta approaches 5 cm or 6 
cm in descending portions. Commonly a diameter approaching 5 cm is 
considered the upper limit for conservative treatment strategies. 
 Progression of enlargement: subsequent progression of aortic dimensions 
mandates early replacement. 
 Family history of dissection 
 Grade of aortic valve regurgitation. Operation should be performed before 
an increase in left ventricular end systolic dimension is noted, in order to 
prevent irreversible damage to the left ventricle and to improve long term 
prognosis. 
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Surgical techniques 
A recent survey of 10 major Marfan surgical centres reported an overall operative 
mortality rate of 1.5% in patients undergoing elective root replacement. However, 
differences became apparent when emergency procedures were performed for acute 
dissection which resulted in an eight fold increased mortality rate (11.6%) in contrast 
to elective surgery.8 
 
Ascending thoracic aorta 
In 1968 the composite graft technique with replacement of the aortic valve, the sinus 
of Valsalva and the ascending aorta was introduced by Bentall and de Bono.9 Briefly, 
this technique consists of a composite graft consist of a mechanical valve inserted 
into a gelatine impregnated Dacron graft that comes preassembled. The coronary 
arteries are reimplanted as buttons on to the graft. However, in order to avoid life 
long anticoagulation, subsequent efforts were directed towards preserving the aortic 
valve and thereby obviating the need for continuous anticoagulation. Valve sparing 
aortic root replacements were subsequently introduced by Yacoub as remodelling 
techniques in 1979 and by David with the reimplantation procedure in 1988.10,11 
Preservation of the aortic valve has many advantages namely preservation of the 
dynamic structure of the outflow tract which influences left ventricular function, 
coronary flow and cardiac output.12 A recent study by de Oliviera and colleagues 
compared aortic valve reimplantation versus remodelling of the aortic root technique; 
the reimplantation group emerged as more appropriate for prevention of further root 
dilatation.13 Even though some concern had been raised concerning the durability of 
this procedure as the aortic leaflets are involved in fibrillin deficiency, long term 
results have been encouraging (figures 4,5).13 
Furthermore as most patients with MFS necessitate subsequent vascular or 
orthopaedic interventions, the avoidance of anticoagulation results in a diminished 
risk of bleeding complications. 
 
Figure 4 Ascending aortic aneurysm intraoperative view from the patient in figure 3. 
A=right ventricle, B=venous cannula in right atrium, C=ascending aortic aneurysm 
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Figure 5 Intraoperative view of a replaced ascending aorta with a gelatine coated 
Dacron prosthesis (A). Anastomoses are usually augmented with Teflon felt strips 
(B). 
 
 
Descending thoracic aorta 
The risk of additional aneurysm formation after intervention on the ascending aorta is 
around 50%. The majority of patients need further surgery in the remaining aorta 
followed by the iliac and subclavian artery. In a previous study by Finkbohner and 
colleagues, it was determined that the presence of aortic dissection, hypertension 
and history of smoking are risk factors for the development of secondary aneurysms. 
Moreover, patients with a dissection at the time of first surgery were more likely to 
require subsequent surgery on the remaining aorta as outlined in the current study. 
The ascending thoracic aorta was the site of first operation in 84% of their patients, 
followed by the descending thoracic aorta and the abdominal aorta. Median age at 
the time of first operation was 32 years.14 
A recent publication by Coselli et al reported a favourable experience of replacement 
of the ascending thoracic aorta with contemporary techniques in 50 Marfan patients 
with an overall complication rate of 5% and 96% 30 day survival.15 
Endovascular stent grafting (ESG) of the descending aorta emerged as promising 
less invasive alternative for conventional open surgical repair.16 Particularly in 
patients with MFS conservative treatment as usually advocated in an uncomplicated 
acute aortic dissection type B seems less reliable because of the fragility of the aortic 
wall. Therefore more aggressive treatment methods are warranted. With the 
implementation of ESG it became feasible to treat those patients, who would 
otherwise have to undergo emergency surgery with an increased risk of 
complications. Moreover the presence of ESG does not preclude further surgery on 
the aorta, as the can be easily removed. 
However, long term results for ESG are still limited. In our series of 80 patients 
treated with ESG for thoracic aortic disease 4 (5%) needed further open surgical 
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repair. Particularly, we do not recommend ESG for descending aortic aneurysm in 
MFS as through the decreased elasticity of the aortic wall, the radial forces 
generated by the expanded stent graft may result in endoleak formation or potential 
rupture. Longer follow up is definitely needed to predict more accurately the long 
term durability of these devices (figure 6). 
 
Figure 6 Acute type B Dissection beginning distal the left subclavian artery A. A 
typical stent-graft consists of a nitinol wire stent shaped in a zigzag formation, which 
is covered with extra-thin polyester (Dacron) A straight nitinol wire secures the length 
of the device and avoids twisting or kinking. This self-expandable stent-graft is 
compressed over a placement catheter. B. Both the stent-graft and the catheter are 
loaded into a polyurethane sheath for insertion. C. The endoluminal stent-graft 
system is passed over the guidewire and positioned at the desired location as 
determined by intraoperative angiography. D. After exact positioning, the stent-graft 
is released by removing the sheath. E. Exact modelling of the stent onto the aortic 
wall with a balloon. F. Successful exclusion of the entry tear with no detectable filling 
of the aneurysmal sack. 
 
 
T Fleck, M Czerny, E Wolner, and M Grabenwoger. Interventional treatment methods in patients with 
Marfan Syndrome. Images Paediatr Cardiol. 2004 Apr-Jun; 6(2): 1–11.  
 8 
Open repair of the thoracoabdominal aorta with Left heart bypass and selective 
visceral perfusion 
Aneurysms of the thoracoabdominal aorta (TAAA) are mainly the long term result of 
a chronic dissected aorta (figures 7,8). 
 
Figure 7 TAAA aneurysm with involvement of the entire descending thoracic and 
abdominal aorta. A: Proximal descending aorta. B: Distal descending aorta. C: 
Abdominal aorta 
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Figure 8 Same patient after replacement of the TAAA with a Dacron prosthesis. 
A=Aneurysm sac. The visceral and renal vessels have been reimplanted as patch. 
One renal artery was implanted via an 8 mm Dacron graft (B). Intercostal arteries, 
especially in the region from Th 8 to L2 were reimplanted to reduce the risk of 
postoperative spinal cord ischemia and paraplegia (C). D=Lung, E=Bowel. 
 
 
Extended repair of a TAAA was associated with high mortality and complication rates 
until Coselli developed a technique with the aid of left heart bypass, sequential 
clamping and selective visceral perfusion to obviate the need for cardiopulmonary 
bypass and the associated bleeding problems and on the other hand improve end 
organ perfusion, especially of the spinal cord in order to reduce the incidence of 
postoperative paraplegia.15 
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Conclusions 
The primary life threatening complication in MFS patients is rupture of an aortic 
aneurysm. In the era before cardiac surgery over 90% of patients died from 
aneurysm rupture. Through refinements, particular in cardiovascular surgery, life 
expectancy has substantially increased during the last 20 years. Whereas in 1972 
the median life expectancy was 32 years, these numbers rose to 45 years in 1998.17 
This was mainly accomplished through elective replacement of the aortic root which 
prolonged survival in MFS patients as reported previously.17 The presence of 
dissection and hypertension emerged to be a significant predictor of subsequent 
aneurysm operation. It has to be stressed that prophylactic surgery does not 
decrease the risk of sudden death from aneurysm rupture but decreases the risk of 
subsequent vascular complications. The presence of dissection is considered a risk 
factor for future vascular complications most probably through the underlying severe 
pathology. 
A typical pattern of aneurysm formation has been observed, with the ascending 
thoracic aorta being the first vascular event followed by the descending thoracic 
aorta. Notably, peripheral vascular arteries are usually not affected. As more than 
50% of Marfan patients require subsequent surgery on their vascular system, 
recurrent evaluation of the entire aorta by computed tomography or magnetic 
resonance imaging is crucial to the clinical follow up, before and after aortic root 
surgery. 
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